Royal Bank Of Canada Provention Bio, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$6.7 - $24.21 $63,918 - $230,963	-9,540 Reduced 72.89%	3,549 $85,000
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $24,046 - $56,232	5,320 Added 68.48%	13,089 $138,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $16,649 - $27,279	4,854 Added 166.52%	7,769 $35,000
Q2 2022 Aug 15, 2022	SELL	$3.65 - $7.3 $15,143 - $30,287	-4,149 Reduced 58.73%	2,915 $11,000
Q1 2022 May 16, 2022	SELL	$3.4 - $7.88 $16,643 - $38,572	-4,895 Reduced 40.93%	7,064 $51,000
Q4 2021 Feb 14, 2022	BUY	$5.59 - $7.39 $29,151 - $38,538	5,215 Added 77.33%	11,959 $67,000
Q3 2021 Nov 15, 2021	BUY	$5.66 - $8.33 $1,188 - $1,749	210 Added 3.21%	6,744 $43,000
Q2 2021 Aug 16, 2021	BUY	$6.71 - $11.04 $43,843 - $72,135	6,534 New	6,534 $55,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.